APO Research
Talk to an analyst

APO RESEARCH · REPORT

Vaccine (Include COVID-19)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Vaccine (Include COVID-19) Market Outlook and Growth Opportunities 2026

21 December 2025203 pages

Choose your research edition.

Industry ResearchVaccine (Include COVID-19) Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Vaccine (Include COVID-19) Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Vaccine (Include COVID-19) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vaccine (Include COVID-19) Market Outlook and Growth Opportunities 2026203 pages · $4,250 USDMarket Analysis & ForecastGlobal Vaccine (Include COVID-19) Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global Vaccine (Include COVID-19) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Vaccine (Include COVID-19) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Vaccine (Include COVID-19) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Vaccine (Include COVID-19) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Vaccine (Include COVID-19) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Vaccine (Include COVID-19) market include Sanofi, Merck, Pfizer, GSK, AstraZeneca, Zhejiang Pukang, Walvax Biotechnology, Viatris and Sinovac, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Vaccine (Include COVID-19) market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Vaccine (Include COVID-19) and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Vaccine (Include COVID-19) revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Vaccine (Include COVID-19) market.

Vaccine (Include COVID-19) Segment by Company

Sanofi

Merck

Pfizer

GSK

AstraZeneca

Zhejiang Pukang

Walvax Biotechnology

Viatris

Sinovac

Sinovac

Serum Institute

Panacea Biotec Ltd

LG Life Sciences

KM Biologics

Hualan Bio

Halfkin Bio-Pharmaceuticals

CSL

Changchun Institute of Biological

Bio-Med

Bharat Biotech

Vaccine (Include COVID-19) Segment by Type

Inactivated Vaccine

Attenuated Vaccine

mRNA

Other

Vaccine (Include COVID-19) Segment by Application

Public

Private

Vaccine (Include COVID-19) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Vaccine (Include COVID-19) status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Vaccine (Include COVID-19) key companies, revenue, market share, and recent developments.

3. To split the Vaccine (Include COVID-19) breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Vaccine (Include COVID-19) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Vaccine (Include COVID-19) significant trends, drivers, influence factors in global and regions.

6. To analyze Vaccine (Include COVID-19) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vaccine (Include COVID-19) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vaccine (Include COVID-19) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vaccine (Include COVID-19).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Vaccine (Include COVID-19) industry.

Chapter 3: Detailed analysis of Vaccine (Include COVID-19) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Vaccine (Include COVID-19) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Vaccine (Include COVID-19) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Vaccine (Include COVID-19) Industry Trends Table 2. Vaccine (Include COVID-19) Industry Drivers Table 3. Vaccine (Include COVID-19) Industry Opportunities and Challenges Table 4. Vaccine (Include COVID-19) Industry Restraints Table 5. Global Vaccine (Include COVID-19) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Vaccine (Include COVID-19) Revenue Share by Company (2021-2026) Table 7. Global Vaccine (Include COVID-19) Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Vaccine (Include COVID-19) Key Company Manufacturing Base & Headquarters Table 9. Global Vaccine (Include COVID-19) Company, Product Type & Application Table 10. Global Vaccine (Include COVID-19) Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Vaccine (Include COVID-19) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Inactivated Vaccine Table 15. Significant Companies of Attenuated Vaccine Table 16. Significant Companies of mRNA Table 17. Significant Companies of Other Table 18. Global Vaccine (Include COVID-19) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Vaccine (Include COVID-19) Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Vaccine (Include COVID-19) Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Vaccine (Include COVID-19) Sales Value Share by Type (2021-2026) Table 22. Global Vaccine (Include COVID-19) Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Public Table 24. Significant Companies of Private Table 25. Global Vaccine (Include COVID-19) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Vaccine (Include COVID-19) Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Vaccine (Include COVID-19) Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Vaccine (Include COVID-19) Sales Value Share by Application (2021-2026) Table 29. Global Vaccine (Include COVID-19) Sales Value Share by Application (2027-2032) Table 30. Global Vaccine (Include COVID-19) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Vaccine (Include COVID-19) Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Vaccine (Include COVID-19) Sales Value Share by Region (2021-2026) Table 33. Global Vaccine (Include COVID-19) Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Vaccine (Include COVID-19) Sales Value Share by Region (2027-2032) Table 35. Global Vaccine (Include COVID-19) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Vaccine (Include COVID-19) Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Vaccine (Include COVID-19) Sales Value Market Share by Country (2021-2026) Table 38. Global Vaccine (Include COVID-19) Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Vaccine (Include COVID-19) Sales Value Market Share by Country (2027-2032) Table 40. Sanofi Company Information Table 41. Sanofi Business Overview Table 42. Sanofi Vaccine (Include COVID-19) Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Sanofi Vaccine (Include COVID-19) Product Portfolio Table 44. Sanofi Recent Development Table 45. Merck Company Information Table 46. Merck Business Overview Table 47. Merck Vaccine (Include COVID-19) Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Merck Vaccine (Include COVID-19) Product Portfolio Table 49. Merck Recent Development Table 50. Pfizer Company Information Table 51. Pfizer Business Overview Table 52. Pfizer Vaccine (Include COVID-19) Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Pfizer Vaccine (Include COVID-19) Product Portfolio Table 54. Pfizer Recent Development Table 55. GSK Company Information Table 56. GSK Business Overview Table 57. GSK Vaccine (Include COVID-19) Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. GSK Vaccine (Include COVID-19) Product Portfolio Table 59. GSK Recent Development Table 60. AstraZeneca Company Information Table 61. AstraZeneca Business Overview Table 62. AstraZeneca Vaccine (Include COVID-19) Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. AstraZeneca Vaccine (Include COVID-19) Product Portfolio Table 64. AstraZeneca Recent Development Table 65. Zhejiang Pukang Company Information Table 66. Zhejiang Pukang Business Overview Table 67. Zhejiang Pukang Vaccine (Include COVID-19) Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Zhejiang Pukang Vaccine (Include COVID-19) Product Portfolio Table 69. Zhejiang Pukang Recent Development Table 70. Walvax Biotechnology Company Information Table 71. Walvax Biotechnology Business Overview Table 72. Walvax Biotechnology Vaccine (Include COVID-19) Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Walvax Biotechnology Vaccine (Include COVID-19) Product Portfolio Table 74. Walvax Biotechnology Recent Development Table 75. Viatris Company Information Table 76. Viatris Business Overview Table 77. Viatris Vaccine (Include COVID-19) Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Viatris Vaccine (Include COVID-19) Product Portfolio Table 79. Viatris Recent Development Table 80. Sinovac Company Information Table 81. Sinovac Business Overview Table 82. Sinovac Vaccine (Include COVID-19) Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Sinovac Vaccine (Include COVID-19) Product Portfolio Table 84. Sinovac Recent Development Table 85. Sinovac Company Information Table 86. Sinovac Business Overview Table 87. Sinovac Vaccine (Include COVID-19) Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Sinovac Vaccine (Include COVID-19) Product Portfolio Table 89. Sinovac Recent Development Table 90. Serum Institute Company Information Table 91. Serum Institute Business Overview Table 92. Serum Institute Vaccine (Include COVID-19) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. Serum Institute Vaccine (Include COVID-19) Product Portfolio Table 94. Serum Institute Recent Development Table 95. Panacea Biotec Ltd Company Information Table 96. Panacea Biotec Ltd Business Overview Table 97. Panacea Biotec Ltd Vaccine (Include COVID-19) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. Panacea Biotec Ltd Vaccine (Include COVID-19) Product Portfolio Table 99. Panacea Biotec Ltd Recent Development Table 100. LG Life Sciences Company Information Table 101. LG Life Sciences Business Overview Table 102. LG Life Sciences Vaccine (Include COVID-19) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 103. LG Life Sciences Vaccine (Include COVID-19) Product Portfolio Table 104. LG Life Sciences Recent Development Table 105. KM Biologics Company Information Table 106. KM Biologics Business Overview Table 107. KM Biologics Vaccine (Include COVID-19) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 108. KM Biologics Vaccine (Include COVID-19) Product Portfolio Table 109. KM Biologics Recent Development Table 110. Hualan Bio Company Information Table 111. Hualan Bio Business Overview Table 112. Hualan Bio Vaccine (Include COVID-19) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 113. Hualan Bio Vaccine (Include COVID-19) Product Portfolio Table 114. Hualan Bio Recent Development Table 115. Halfkin Bio-Pharmaceuticals Company Information Table 116. Halfkin Bio-Pharmaceuticals Business Overview Table 117. Halfkin Bio-Pharmaceuticals Vaccine (Include COVID-19) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 118. Halfkin Bio-Pharmaceuticals Vaccine (Include COVID-19) Product Portfolio Table 119. Halfkin Bio-Pharmaceuticals Recent Development Table 120. CSL Company Information Table 121. CSL Business Overview Table 122. CSL Vaccine (Include COVID-19) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 123. CSL Vaccine (Include COVID-19) Product Portfolio Table 124. CSL Recent Development Table 125. Changchun Institute of Biological Company Information Table 126. Changchun Institute of Biological Business Overview Table 127. Changchun Institute of Biological Vaccine (Include COVID-19) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 128. Changchun Institute of Biological Vaccine (Include COVID-19) Product Portfolio Table 129. Changchun Institute of Biological Recent Development Table 130. Bio-Med Company Information Table 131. Bio-Med Business Overview Table 132. Bio-Med Vaccine (Include COVID-19) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 133. Bio-Med Vaccine (Include COVID-19) Product Portfolio Table 134. Bio-Med Recent Development Table 135. Bharat Biotech Company Information Table 136. Bharat Biotech Business Overview Table 137. Bharat Biotech Vaccine (Include COVID-19) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 138. Bharat Biotech Vaccine (Include COVID-19) Product Portfolio Table 139. Bharat Biotech Recent Development Table 140. Research Programs/Design for This Report Table 141. Authors List of This Report Table 142. Secondary Sources Table 143. Primary Sources List of Figures Figure 1. Vaccine (Include COVID-19) Product Image Figure 2. Global Vaccine (Include COVID-19) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vaccine (Include COVID-19) Market Size (2021-2032) & (US$ Million) Figure 4. Global Vaccine (Include COVID-19) Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Inactivated Vaccine Image Figure 8. Attenuated Vaccine Image Figure 9. mRNA Image Figure 10. Other Image Figure 11. Global Vaccine (Include COVID-19) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Vaccine (Include COVID-19) Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Vaccine (Include COVID-19) Sales Value Share by Type (2021-2032) Figure 14. Public Image Figure 15. Private Image Figure 16. Global Vaccine (Include COVID-19) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Vaccine (Include COVID-19) Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Vaccine (Include COVID-19) Sales Value Share by Application (2021-2032) Figure 19. Global Vaccine (Include COVID-19) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Vaccine (Include COVID-19) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Vaccine (Include COVID-19) Sales Value (2021-2032) & (US$ Million) Figure 22. North America Vaccine (Include COVID-19) Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Vaccine (Include COVID-19) Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Vaccine (Include COVID-19) Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Vaccine (Include COVID-19) Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Vaccine (Include COVID-19) Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Vaccine (Include COVID-19) Sales Value (2021-2032) & (US$ Million) Figure 28. South America Vaccine (Include COVID-19) Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Vaccine (Include COVID-19) Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Vaccine (Include COVID-19) Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Inactivated Vaccine
  • Attenuated Vaccine
  • mRNA
  • Other
Applications
  • Public
  • Private
Companies covered
  • Sanofi
  • Merck
  • Pfizer
  • GSK
  • AstraZeneca
  • Zhejiang Pukang
  • Walvax Biotechnology
  • Viatris
  • Sinovac
  • Sinovac
  • Serum Institute
  • Panacea Biotec Ltd
  • LG Life Sciences
  • KM Biologics
  • Hualan Bio
  • Halfkin Bio-Pharmaceuticals
  • CSL
  • Changchun Institute of Biological
  • Bio-Med
  • Bharat Biotech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Vaccine (Include COVID-19) Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Vaccine (Include COVID-19) Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Vaccine (Include COVID-19) Market Dynamics
  1. 2.1 Vaccine (Include COVID-19) Industry Trends
  2. 2.2 Vaccine (Include COVID-19) Industry Drivers
  3. 2.3 Vaccine (Include COVID-19) Industry Opportunities and Challenges
  4. 2.4 Vaccine (Include COVID-19) Industry Restraints
3 Vaccine (Include COVID-19) Market by Company
  1. 3.1 Global Vaccine (Include COVID-19) Company Revenue Ranking in 2025
  2. 3.2 Global Vaccine (Include COVID-19) Revenue by Company (2021-2026)
  3. 3.3 Global Vaccine (Include COVID-19) Company Ranking (2024-2026)
  4. 3.4 Global Vaccine (Include COVID-19) Company Manufacturing Base and Headquarters
  5. 3.5 Global Vaccine (Include COVID-19) Company Product Type and Application
  6. 3.6 Global Vaccine (Include COVID-19) Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Vaccine (Include COVID-19) Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Vaccine (Include COVID-19) Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Vaccine (Include COVID-19) Market by Type
  1. 4.1 Vaccine (Include COVID-19) Type Introduction
  2. 4.1.1 Inactivated Vaccine
  3. 4.1.2 Attenuated Vaccine
  4. 4.1.3 mRNA
  5. 4.1.4 Other
  6. 4.2 Global Vaccine (Include COVID-19) Sales Value by Type
  7. 4.2.1 Global Vaccine (Include COVID-19) Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Vaccine (Include COVID-19) Sales Value by Type (2021-2032)
  9. 4.2.3 Global Vaccine (Include COVID-19) Sales Value Share by Type (2021-2032)
5 Vaccine (Include COVID-19) Market by Application
  1. 5.1 Vaccine (Include COVID-19) Application Introduction
  2. 5.1.1 Public
  3. 5.1.2 Private
  4. 5.2 Global Vaccine (Include COVID-19) Sales Value by Application
  5. 5.2.1 Global Vaccine (Include COVID-19) Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Vaccine (Include COVID-19) Sales Value by Application (2021-2032)
  7. 5.2.3 Global Vaccine (Include COVID-19) Sales Value Share by Application (2021-2032)
6 Vaccine (Include COVID-19) Regional Value Analysis
  1. 6.1 Global Vaccine (Include COVID-19) Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Vaccine (Include COVID-19) Sales Value by Region (2021-2032)
  3. 6.2.1 Global Vaccine (Include COVID-19) Sales Value by Region: 2021-2026
  4. 6.2.2 Global Vaccine (Include COVID-19) Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Vaccine (Include COVID-19) Sales Value (2021-2032)
  7. 6.3.2 North America Vaccine (Include COVID-19) Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Vaccine (Include COVID-19) Sales Value (2021-2032)
  10. 6.4.2 Europe Vaccine (Include COVID-19) Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Vaccine (Include COVID-19) Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Vaccine (Include COVID-19) Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Vaccine (Include COVID-19) Sales Value (2021-2032)
  16. 6.6.2 South America Vaccine (Include COVID-19) Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Vaccine (Include COVID-19) Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Vaccine (Include COVID-19) Sales Value Share by Country, 2025 VS 2032
7 Vaccine (Include COVID-19) Country-level Value Analysis
  1. 7.1 Global Vaccine (Include COVID-19) Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Vaccine (Include COVID-19) Sales Value by Country (2021-2032)
  3. 7.2.1 Global Vaccine (Include COVID-19) Sales Value by Country (2021-2026)
  4. 7.2.2 Global Vaccine (Include COVID-19) Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Vaccine (Include COVID-19) Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Vaccine (Include COVID-19) Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Vaccine (Include COVID-19) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Vaccine (Include COVID-19) Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Vaccine (Include COVID-19) Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck Vaccine (Include COVID-19) Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck Vaccine (Include COVID-19) Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 Pfizer
  14. 8.3.1 Pfizer Company Information
  15. 8.3.2 Pfizer Business Overview
  16. 8.3.3 Pfizer Vaccine (Include COVID-19) Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Vaccine (Include COVID-19) Product Portfolio
  18. 8.3.5 Pfizer Recent Developments
  19. 8.4 GSK
  20. 8.4.1 GSK Company Information
  21. 8.4.2 GSK Business Overview
  22. 8.4.3 GSK Vaccine (Include COVID-19) Revenue and Gross Margin (2021-2026)
  23. 8.4.4 GSK Vaccine (Include COVID-19) Product Portfolio
  24. 8.4.5 GSK Recent Developments
  25. 8.5 AstraZeneca
  26. 8.5.1 AstraZeneca Company Information
  27. 8.5.2 AstraZeneca Business Overview
  28. 8.5.3 AstraZeneca Vaccine (Include COVID-19) Revenue and Gross Margin (2021-2026)
  29. 8.5.4 AstraZeneca Vaccine (Include COVID-19) Product Portfolio
  30. 8.5.5 AstraZeneca Recent Developments
  31. 8.6 Zhejiang Pukang
  32. 8.6.1 Zhejiang Pukang Company Information
  33. 8.6.2 Zhejiang Pukang Business Overview
  34. 8.6.3 Zhejiang Pukang Vaccine (Include COVID-19) Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Zhejiang Pukang Vaccine (Include COVID-19) Product Portfolio
  36. 8.6.5 Zhejiang Pukang Recent Developments
  37. 8.7 Walvax Biotechnology
  38. 8.7.1 Walvax Biotechnology Company Information
  39. 8.7.2 Walvax Biotechnology Business Overview
  40. 8.7.3 Walvax Biotechnology Vaccine (Include COVID-19) Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Walvax Biotechnology Vaccine (Include COVID-19) Product Portfolio
  42. 8.7.5 Walvax Biotechnology Recent Developments
  43. 8.8 Viatris
  44. 8.8.1 Viatris Company Information
  45. 8.8.2 Viatris Business Overview
  46. 8.8.3 Viatris Vaccine (Include COVID-19) Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Viatris Vaccine (Include COVID-19) Product Portfolio
  48. 8.8.5 Viatris Recent Developments
  49. 8.9 Sinovac
  50. 8.9.1 Sinovac Company Information
  51. 8.9.2 Sinovac Business Overview
  52. 8.9.3 Sinovac Vaccine (Include COVID-19) Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Sinovac Vaccine (Include COVID-19) Product Portfolio
  54. 8.9.5 Sinovac Recent Developments
  55. 8.10 Sinovac
  56. 8.10.1 Sinovac Company Information
  57. 8.10.2 Sinovac Business Overview
  58. 8.10.3 Sinovac Vaccine (Include COVID-19) Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Sinovac Vaccine (Include COVID-19) Product Portfolio
  60. 8.10.5 Sinovac Recent Developments
  61. 8.11 Serum Institute
  62. 8.11.1 Serum Institute Company Information
  63. 8.11.2 Serum Institute Business Overview
  64. 8.11.3 Serum Institute Vaccine (Include COVID-19) Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Serum Institute Vaccine (Include COVID-19) Product Portfolio
  66. 8.11.5 Serum Institute Recent Developments
  67. 8.12 Panacea Biotec Ltd
  68. 8.12.1 Panacea Biotec Ltd Company Information
  69. 8.12.2 Panacea Biotec Ltd Business Overview
  70. 8.12.3 Panacea Biotec Ltd Vaccine (Include COVID-19) Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Panacea Biotec Ltd Vaccine (Include COVID-19) Product Portfolio
  72. 8.12.5 Panacea Biotec Ltd Recent Developments
  73. 8.13 LG Life Sciences
  74. 8.13.1 LG Life Sciences Company Information
  75. 8.13.2 LG Life Sciences Business Overview
  76. 8.13.3 LG Life Sciences Vaccine (Include COVID-19) Revenue and Gross Margin (2021-2026)
  77. 8.13.4 LG Life Sciences Vaccine (Include COVID-19) Product Portfolio
  78. 8.13.5 LG Life Sciences Recent Developments
  79. 8.14 KM Biologics
  80. 8.14.1 KM Biologics Company Information
  81. 8.14.2 KM Biologics Business Overview
  82. 8.14.3 KM Biologics Vaccine (Include COVID-19) Revenue and Gross Margin (2021-2026)
  83. 8.14.4 KM Biologics Vaccine (Include COVID-19) Product Portfolio
  84. 8.14.5 KM Biologics Recent Developments
  85. 8.15 Hualan Bio
  86. 8.15.1 Hualan Bio Company Information
  87. 8.15.2 Hualan Bio Business Overview
  88. 8.15.3 Hualan Bio Vaccine (Include COVID-19) Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Hualan Bio Vaccine (Include COVID-19) Product Portfolio
  90. 8.15.5 Hualan Bio Recent Developments
  91. 8.16 Halfkin Bio-Pharmaceuticals
  92. 8.16.1 Halfkin Bio-Pharmaceuticals Company Information
  93. 8.16.2 Halfkin Bio-Pharmaceuticals Business Overview
  94. 8.16.3 Halfkin Bio-Pharmaceuticals Vaccine (Include COVID-19) Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Halfkin Bio-Pharmaceuticals Vaccine (Include COVID-19) Product Portfolio
  96. 8.16.5 Halfkin Bio-Pharmaceuticals Recent Developments
  97. 8.17 CSL
  98. 8.17.1 CSL Company Information
  99. 8.17.2 CSL Business Overview
  100. 8.17.3 CSL Vaccine (Include COVID-19) Revenue and Gross Margin (2021-2026)
  101. 8.17.4 CSL Vaccine (Include COVID-19) Product Portfolio
  102. 8.17.5 CSL Recent Developments
  103. 8.18 Changchun Institute of Biological
  104. 8.18.1 Changchun Institute of Biological Company Information
  105. 8.18.2 Changchun Institute of Biological Business Overview
  106. 8.18.3 Changchun Institute of Biological Vaccine (Include COVID-19) Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Changchun Institute of Biological Vaccine (Include COVID-19) Product Portfolio
  108. 8.18.5 Changchun Institute of Biological Recent Developments
  109. 8.19 Bio-Med
  110. 8.19.1 Bio-Med Company Information
  111. 8.19.2 Bio-Med Business Overview
  112. 8.19.3 Bio-Med Vaccine (Include COVID-19) Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Bio-Med Vaccine (Include COVID-19) Product Portfolio
  114. 8.19.5 Bio-Med Recent Developments
  115. 8.20 Bharat Biotech
  116. 8.20.1 Bharat Biotech Company Information
  117. 8.20.2 Bharat Biotech Business Overview
  118. 8.20.3 Bharat Biotech Vaccine (Include COVID-19) Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Bharat Biotech Vaccine (Include COVID-19) Product Portfolio
  120. 8.20.5 Bharat Biotech Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst